| 19th May 2016
As a creative marketing consultancy, we have a unique perspective on the challenges facing the broad range of stakeholders in the healthcare and pharma industry. As such, we've created this magazine to explore those challenges in depth from a variety of viewpoints.
In this supplementary issue, we’re taking a special look at immunotherapies, and more specifically, the growing buzz around “immuno-oncology” therapies. At the time of publication, Blue Latitude Health have worked with four of the eight immunotherapies currently approved by the FDA, so we’ve pooled our expertise across the different capabilities to give you a clear view on the fourth pillar of care in oncology.
| 11th January 2018
Senior Associate Consultant Jiayi Chen explains the benefits and pitfalls of programmatic advertising and reveals how it can impact return on investment in your marketing campaigns.
| 4th January 2018
Measuring marketing activity is proving to be a major challenge in pharma. Here, Senior Consultant Paul Townley-Jones explores the meaning of success and gives his tips for measuring efficiency and effectiveness, along with the formula for calculating profit and ROI.
| 5th December 2017
Pharma is making measured progress in its adoption of multichannel marketing. But can it actually measure success? And does it even know what good looks like? Chris Ross interviews Senior Consultant Paul Towney Jones to explore the risks and benefits of increased investment in MCM.